>PROKKA_00001 Clostridium P-47 protein
MQTTTLNWDTVYAVPINIVNEAIKLKHPTPENFELLNGKYGNCSGSFEEWQITNGGDGSN
IRLKIPIKNFKATIIGNRLNGKGGFAFANLEVQVKLKYLPHFPQSKNKDIELVDLKIRTQ
SDNPEDPAIIVISSYKNIQGFYFEDEYKLTEDDEFVVSYFYRLIKEWLEKNLHFFNYIFN
TVNLNLYISDKEKWEWTKPSYVDYAYSEIEGDLSRSALGVLCMTGGRTGSKNQQQKIDPY
AIPKKSQSGFLISEERLLRNILLPTIPKKFPKSKGDEFEVINESSQGGGYSYILKLKKGK
KIDLENIQAVGYTCTPYIQEMKIYLLGSYLKLETTTRVDLPLGVASICETTCEYKFKLST
NNKGEQTIAYEQIGSPVNIQYSENTGNVGLNIVVSFLSATLSFALTFVPGFGTFLAVGLI
GGCLIGSVALIPTFIESYNSDTAPSIDLSLENSVSEITWNSSDVFNLDYVALAGPLQLGG
TLQVQNS*
>PROKKA_00002 Clostridium P-47 protein
MKKIYYKFHKGGILMTNLKPYIIYDWKETILKNSKDNYSINESIPKIFSKKICGGRFFNS
TLSGNWKSWTLTDEGEGPHPVLKCTIDNGYLEIYSNTSSEKHSLKDIEIKVCMSIKPNSD
GTHSLCKNSFYIKTNSLKLSEDRLILSHCLDKLILAWFKDNHKYIELFINRSRIQTRVEG
DLSLLGWDIESSVSYKTMNEFIKKDNLYEKKFHQYMEVRRNEYTIDGEFGPWQMTTGADG
QNIRFLCPIKSATYKINDDVYIAKPDNFIIIQVDLKYFDSKTTIIDPSGLNNGQQFNLKV
KTDSTDEINAVILVGSRITDVNEDLYPGDDVSLEIVFKTWFNANIQKFTQIFSYILLNET
SKIPEYQWLKPTQISYGSASVTMPDPSNPNKELSNLDASTFAAMAMVENHKNDRPNHAVD
NRFLELSKTPAAFAISMPEFLKHFLVTGLQAMQIDNLDAFEVSSENLVITNKKKINFGKI
QDQNRQVDALIEPNNFKLAIQNNQVVVEIVDATWQQVVGVTGHFGYRQAYNLILKNENNV
YKPMLEESGDVTISYMVTEEAWKTTQDAIISATVGLVVGTIIGTAFSKLSDKLYKFLKSK
FIVKNKKASLKISGKDINEVIEMSDLSKPQLLSIKKANAKISTEEVGLISQNGSTSLENL
AIFKNKPRPIGERVQILGLKLVSGLITTFGWSIGFVLPDILKDVINANINNNFEVLPGIQ
QFTQQCIGSIQWPDNSELKIDFAKLQGVYLLGGNLVKIPESN*
>PROKKA_00003 hypothetical protein
MELKQAFVFEFDENLSSSSGSIHLEKVKQNCSPNYDYFKITFIDGYLYIKNKSGVILDKY
DLKNVISLVALKRDYLSLSLSNNKQIKKFKNIKNKHLKNKFNLYVINEDIEKRITKNGIL
EEVILNKMLLSILLGNEENLLQIS*
>PROKKA_00004 Clostridium P-47 protein
MNTYGWDIVYGCSNRVVNKHLKNYIDENKIEFLYSDINKKQEIKMIFDNWEIINGGTSNF
LRIKIFIKEGYFKFRNTTVDLSGVIPILEIKLDFFNDASNPHIKELKFSFGNKTNDDIKV
IVSDLSGKLYEEDEFYFNKLLISAFINNEKQVSYIFASLNVTSNIVWMNPKQFKFVYYSP
TDNNDGYLCILSVVTNRDISKLSTNVDSSILSENSEVGLLISEKLFMENLLLPKLSSNMG
SNITSNNFNVINTSDTTGIIKNKNTLNWYGIKVAALYYYPEINDFSMELFEGNKLKTRLS
GIVKLTGYERIYSKLNMECITKFIYDNKNKKVSFEIYSTPIMECRPIFGLLDGIPAAVAK
SVGNWSLKSFRDSLAFELANNFTDIINDIVNWNNLKISEVTNIILNVGFCIQGNMN*
>PROKKA_00005 Tetanus toxin precursor
MKINGNLNIDSPVDNKNVAIVRSRKSDVFFKAFQVAPNIWIVPERYYGESLKINEDQKFD
GGIYDSNFLSTNNEKDDFLQATIKLLQRINNNVVGAKLLSLISTAIPFPYENNTEDYRQT
NYLSSKNNEHYYTANLVIFGPGSNIIKNNVIYYKKEYAESGMGTMLEIWFQPFLTHKYDE
FYVDPALELIKCLIKSLYYLYGIKPNDNLNIPYRLRNEFNSLEYSELDMIDFLISGGIDY
KLLNTNPYWFIDKYFIDTSKNFEKYKNDYEIKIKNNNYIANSIKLYLEQKFKINVKDIWE
LNLSYFSKEFQIMMPERYNNALNHYYRKEYYVIDYFKNYNINGFKNGQIKTKLPLSKYNK
EIINKPELIVNLINQNNTVLMKSNIYGDGLKGTVDNFYSNYIIPYNLNYEHSINYSYLDN
VNIEEIEKIPPINDEDIYPYRKNADTFIPVYNITKAKEINTTTPLPVNYLQAQMIDSNDI
NLSSDFLKVISSKGSLVYSFLNNTMDYLEFIKYDKPIDTDKKYYKWLKAIFRNYSLDITE
TQEISNQFGDTKIIPWIGRALNILNTNNSFVEEFKNLGPISLINKKENITIPKIKIDEIP
SSMLNFSFKDLSENLFNIYCKNNFYLKKIYYNFLDQWWTQYYSQYFDLICMASKSVLAQE
KLIKKLIQKQLRYLMENSNISSTNLILINLTTTNTLRDISNQSQIAINNIDKFFNNAAMC
VFENNIYPKFTSFMEQCIKNINKSTKEFILKCTNINETEKSHLIMQNSFSNLDFDFLDIQ
NMKNLFNSYTELLIKEQTSPYELSLYAFQEQDNNVIGDTSGKNTLVEYPKDIGLVYGINN
NAIHLTGANQNIKFTNDYFENGLTNNFSIYFWLRNLKQNTIKSKLIGSKEDNCGWEIYFE
NDGLVFNIIDSNGNEKNIYLSNISNNSWHYIVISINRLKDQLLIFIDNILVANEDIKEIL
NIYSSDIISLLSDNNNVYIEGLSVLNKTINSNEILTDYFSDLNNSYIRNFDEEILQYNRT
YELFNYVFPEIAINKIEQNNNIYLSINNENNLNFKPLKFKLLNTNPNKQYVQKWDEVIFS
VLDGTEKYLDISTTNNRIQLVDNKNNAQIFIINNDIFISNCLTLTYNNVNVYLSIKNQDY
NWVICDLNHDIPKKSYLWILKNI*
>PROKKA_00006 Botulinum neurotoxin type E precursor
MPKINSFNYNDPVNDRTILYIKPGGCQEFYKSFNIMKNIWIIPERNVIGTTPQDFHPPTS
LKNGDSSYYDPNYLQSDEEKDRFLKIVTKIFNRINNNLSGGILLEELSKANPYLGNDNTP
DNQFHIGDASAVEIKFSNGSQDILLPNVIIMGAEPDLFETNSSNISLRNNYMPSNHGFGS
IAIVTFSPEYSFRFNDNSMNEFIQDPALTLMHELIHSLHGLYGAKGITTKYTITQKQNPL
ITNIRGTNIEEFLTFGGTDLNIITSAQSNDIYTNLLADYKKIASKLSKVQVSNPLLNPYK
DVFEAKYGLDKDASGIYSVNINKFNDIFKKLYSFTEFDLATKFQVKCRQTYIGQYKYFKL
SNLLNDSIYNISEGYNINNLKVNFRGQNANLNPRIITPITGRGLVKKIIRFCKNIVSVKG
IRKSICIEINNGELFFVASENSYNDDNINTPKEIDDTVTSNNNYENDLDQVILNFNSESA
PGLSDEKLNLTIQNDAYIPKYDSNGTSDIEQHDVNELNVFFYLDAQKVPEGENNVNLTSS
IDTALLEQPKIYTFFSSEFINNVNKPVQAALFVSWIQQVLVDFTTEANQKSTVDKIADIS
IVVPYIGLALNIGNEAQKGNFKDALELLGAGILLEFEPELLIPTILVFTIKSFLGSSDNK
NKVIKAINNALKERDEKWKEVYSFIVSNWMTKINTQFNKRKEQMYQALQNQVNAIKTIIE
SKYNSYTLEEKNELTNKYDIKQIENELNQKVSIAMNNIDRFLTESSISYLMKLINEVKIN
KLREYDENVKTYLLNYIIQHGSILGESQQELNSMVTDTLNNSIPFKLSSYTDDKILISYF
NKFFKRIKSSSVLNMRYKNDKYVDTSGYDSNININGDVYKYPTNKNQFGIYNDKLSEVNI
SQNDYIIYDNKYKNFSISFWVRIPNYDNKIVNVNNEYTIINCMRDNNSGWKVSLNHNEII
WTLQDNAGINQKLAFNYGNANGISDYINKWIFVTITNDRLGDSKLYINGNLIDQKSILNL
GNIHVSDNILFKIVNCSYTRYIGIRYFNIFDKELDETEIQTLYSNEPNTNILKDFWGNYL
LYDKEYYLLNVLKPNNFIDRRKDSTLSINNIRSTILLANRLYSGIKVKIQRVNNSSTNDN
LVRKNDQVYINFVASKTHLFPLYADTATTNKEKTIKISSSGNRFNQVVVMNSVGNNCTMN
FKNNNGNNIGLLGFKADTVVASTWYYTHMRDHTNSNGCFWNFISEEHGWQEK*
>PROKKA_00007 Helix-turn-helix domain protein
MNRNIIGKKVRIIRKLKNLTQEELIAIIQLKCLSIDRPMLSRIETDSREVYDFEVKAIAE
ALDISVDELFIQN*
>PROKKA_00008 Replication-associated recombination protein A
MTPLAERMRPTKLEDFVGQKQIIGEGKPLYNIIKSKNIVNCILYGPPGTGKTTLANIMAN
YVDRKFYKLNATTASVKDIQEIASSLDTLLGYNGVVVYIDELQHFSKKQQQSLLEFIEKG
QITLIASTTENPYFVLHKAILSRCNIFTFKPLTTDDIKFGVVKAIERAIENGMEIKYTDD
AISYIAEISQGDYRKAYNILELGIISSLKRTLEITAEYIEELEQSHIRFDASGDEFYNSL
SALQKSIRGSDVDAAIHYLARLIKSGNLTAIVRRLGVIVAEDIGLAHPNALTVVNSGLEL
VLKVGLPEAQLILSELVIYLATLPKSNSAYLAIKSAMQDLENKNVGDVPMHLKDAHYSGA
QKLGVGGYKYPHDYSNNYVKQQYMPQELRDTIYYIPQENKYEGSIKNYWKNIKE*
>PROKKA_00009 hypothetical protein
MGKAGRKENCNISDNDMLVALERYTREFPNEKINIKKLADFSGIERHYWYSRKGLREKIE
EINSISYEKYDIISDGDRKKIKFPNVDEVVDNNFRNKKRLKFILNSFFLTYQDFYESSCE
AYKLKKDINILKDKIIKYEDEIQKLKNERDKFRELSNYNENKYYEIAIRSRERNFRKENN
IKSNVIEINNKNIKAYSTDEDDLDSLLNRIDD*
>PROKKA_00010 hypothetical protein
VNQIANNSDSLVIVTKELKIYKEEELDYYKEKFNYFKKKGRIVNCVFNDLIWTLSETDEG
GYKSNRNIKFSINFINKNNIIKAYLINLLINLININTIVERVRVVSDIINISNFFDIDKF
NEFEEYIESTFDNNKLNMKDYTMNFISFIRDNVDEEYCNYLVSLPNEYFSKTREIPDYTS
ILKFDFLLDKYLKNSDEKEFFRYYPIVLWWKICSKIPLRPCEFMILKKDCVYEKNRKYYI
RIRRCKPHGFVNKALNIRKEQSFRINKEIYDLVMKVVSHKSHDCEFLLSKNLYNKYYTQY
TYKEELVQGRVMRSYNLDKCLKDFYYYEINNKNIQTVISKKDVKESLSQQFYRDCMVSLQ
LGDARHLAIINLVLQGTNSYLIREMCGHRDINSHLHYIDHAKTYITSKVLVLTDIRKLEI
KLANIYSNESFEYGNKRNNKVSNLLYNEYKKVGDIYCKRYVGREEMFPFLCLTDCDECND
KVETDFTGNNDEEIKINKMEIERQFQIIEKYLKDAQFNSIIDSKNERVLFDSQKNIEESA
NKLNYLISKEAELEAKIFFGGIITKEE*
>PROKKA_00011 hypothetical protein
MKQLIKVKEISELSGIDYEEIIESRRYFNGEIVKEQNIEYMHRYDIENIMKNFGYYSIKK
LSKICEISFSTLIRDFNIANFLGIYINFKIDKDFFVDINGVEIILKEFSKNYIATLTLDE
IYRERMKLFPDEFFKTYKLADEFIVKKKRNCYRPYGEDTTSYNRVINSIENLVNYLDKEI
FEYSAEELLKLVSNTNIVKRGYQAHVCQFINYVKRKMRNDCEYNKVFGLTLLTQYKIEKG
ENYLEKIYDKETWSKYYILLKDIDKHIVNAIKDPRYAQSWLYCILNLSVTWRKKNIILSL
PRIKLQEIGVYEFEWFSSKNVFTYSMAELVLNQIKFSLDGVIAYKNRRHLHINIPMSLKI
PTAIAFIICEIHCREKSKDNIMYELAQSYIRKSDYKKLFEDDKLLNFENLKCTRSIISYG
FSHAINTIGTVPAAYKIYSNRRSHSDSEQKITNVTGDHYIALDGIENGAKEFMFHVVERG
AFGFMYYKLFKCFFDKKDFENISQEQLTDLTKYSDQILNPRTLENIADKFIENDRINKLS
IFEILWYSSIIKNKGKRDLSSKSNIFLAIMIDLYKKQSEDLLGKSDEFKTFVDEKYLQLD
AEIEDILKNKISTSKIIDNILNGSNCCYSKDTNCIFDRIERKELCPYKYEDNGGKSCVGC
KYNLLTVYALNEINEKMQTLLDKIQKKSYFTKEEIQKNSYILKNYVSIILEASVHFKNEE
FLSNYINLKMIKTKIYKLKSEGKIINI*
>PROKKA_00012 hypothetical protein
VIELEDAAKEINPKCYKYFMKKLKTLNNINIFDKNGKLFITKNDFEKLKRNKASKIPYHI
DIPNGYASRNEAVKKYNLNYNSLRHNEEKGIIKTAISGGIAFLEKESIEKHIEFLKYIEK
INNDDNWIKVSSLRGKPYYDRISYTVRRNDFKNDLIKIGIGRTAEFFITRKLYKEIINGK
HKIIVTSQHKKRF*
>PROKKA_00013 hypothetical protein
VFIISNVIELRNTNSKYRFKVKVCKYKREGRCEDHLFQKAIIVLFDNITGKSRVHEFTEF
AIREFGKNRIKTQVDYLGKLVKFLNYVIKNKDKKNFKYLDFYDVEEFSQEIALDVQMNTF
NIYKMVLSRFYRYLAQKEWLINVSINDFIIKESEKNGGVMIKYDIPICNIDIPNNIHRRN
THVMEYELQAMLLEVAIEEVNIIALAIFFQMFGGLRSGEIVNLTHSAVQCIGPYGRYGML
LDITDRNLRLDLKNNQAKGYSKKSRKQKVISPFNMLEKIYIQHMKKYKCVDDSGAIFVNK
DGMPMTIGSYNYYFDKLKKIFLKRLKESDNPTLKVQGDILCAAKWKTHIGRGIFSNNLGE
FMSASELKIARGDKYINSSDSYIEETKKIGKLYEENAEGAFQLFIKKINE*
>PROKKA_00014 Replication-associated recombination protein A
MSPLADLMRPSKIEDFVGQRHILGKNTPLYNLIKSKKICNCIFYGPPGTGKTTLANIMAK
YVDKKFYKLNATTASVKDIQNITSELDNLLNYAGVVLYIDELC*
>PROKKA_00015 molybdenum cofactor biosynthesis protein MoaC/MOSC-domain-containing protein
VQGFNLKALPIGSVLTCGNIILEITQIGKECHAHCEIYKKMGECIMPTNGVFAKVIEGGQ
MKIGDEIEIASGIEKMY*
